HOME
 
Company News
June 09 , 2010
Frost & Sullivan Lauds Sorrento Therapeutics for Making Strides in the Global Biopharmaceutical Market
LONDON, June 9 /PRNewswire/ -- Based on its recent research, Frost & Sullivan presents Sorrento Therapeutics Inc. (Sorrento Therapeutics) with the 2010 Global Biopharmaceutical Emerging Company of the Year Award. The human monoclonal antibodies (mAbs) market is teeming with opportunities and was worth nearly $30 billion in 2009, growing at a healthy double digit rate of around 20 per cent. With an increasing number of mAbs attaining blockbuster status, pharmaceutical and biotech companies have been flocking to this market.  
May 21 , 2010
Sorrento Therapeutics Awarded NIH Grant for MRSA Program
Company’s innovative approach to developing vaccines and therapeutics for MRSA receives support from the National Institute of Allergy and Infectious Diseases    
April 14 , 2010
Sorrento Therapeutics Announces Completion of Diverse Library of Full-Length, Fully Human Antibodies
Industry-leading antibody development platform is fast, efficient and unencumbered by third-party royalty obligations   San Diego, April 14, 2010. Sorrento Therapeutics, Inc. (SRNE.OB) today announced that it has completed the construction of an extensive library of full-length, fully human monoclonal antibodies (mAbs). Initial analysis indicates a potential diversity of more than one trillion unique mAbs. The company believes this makes its library the largest full-length, fully human antibody library available for drug discovery and development partnerships. Importantly, Sorrento Therapeutics’ proprietary technologies generate antibodies that are unencumbered by third-party royalty obligations placed on conventional antibody discovery technologies.   
«  1 2 3  »  Pages:(1/3total)